Literature DB >> 2949785

Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.

V Gurewich, R Pannell.   

Abstract

Whereas crude bovine thrombin activated single-chain urokinase-type plasminogen activator (scu-PA), otherwise called pro-urokinase (pro-UK), purified human thrombin converted pro-UK (scu-PA) to a two-chain form that had no amidolytic activity. The two chains (Mr approximately 33,000 and 22,000) were disulfide linked and resistant to subsequent activation by plasmin. By contrast, thrombin did not inactivate tissue plasminogen activator or two-chain urokinase. The enzyme from snake venom Agkistrodon contortrix, relatively specific for fibrinopeptide B, had an effect similar to thrombin, whereas the enzyme from Agkistrodon rhodostoma (ancrod), specific for fibrinopeptide A, did not. When pro-UK (scu-PA) was present during thrombin clotting of fibrinogen, degradation of 125I-pro-UK (scu-PA) in the clot supernatant was seen, whereas virtually full recovery (95%) of radioactivity was found. A loss of latent amidolytic activity in the clot supernatant was also found, the extent of which could be correlated with the degree of degradation of the radiolabeled probe. It was concluded that thrombin inactivation of pro-UK (scu-PA) accounts for the loss of amidolytic activity in the clot supernatant, which has been attributed to fibrin binding. Further confirmation was obtained from experiments in which ancrod was used as the clotting agent. Full recovery of both radioactivity and latent amidolytic activity of pro-UK (scu-PA) in the supernatant was obtained under these conditions. These findings indicate that thrombin may introduce an artifact in the results of certain experiments designed to study the fibrin affinity or fibrinolytic effect of pro-UK (scu-PA).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2949785

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.

Authors:  A V Iakhiaev; A Nalian; K Koenig; S Idell
Journal:  Thromb Res       Date:  2007-02-02       Impact factor: 3.944

2.  Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse.

Authors:  M A Olman; N Mackman; C L Gladson; K M Moser; D J Loskutoff
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

3.  Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin.

Authors:  G A de Munk; E Groeneveld; D C Rijken
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

Review 4.  Thrombolysis in thromboembolic diseases.

Authors:  D C Gulba; R Dechend
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

5.  Role of the glycosaminoglycan component of thrombomodulin in its acceleration of the inactivation of single-chain urokinase-type plasminogen activator by thrombin.

Authors:  G A de Munk; J F Parkinson; E Groeneveld; N U Bang; D C Rijken
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

6.  Plasminogen activators in synovial fluid and plasma from patients with arthritis.

Authors:  E J Brommer; G Dooijewaard; B A Dijkmans; F C Breedveld
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

7.  Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).

Authors:  V Gurewich; R Pannell; R J Broeze; J Mao
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

8.  Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.

Authors:  H Kobayashi; H Ohi; H Shinohara; M Sugimura; T Fujii; T Terao; M Schmitt; L Goretzki; N Chucholowski; F Jänicke
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.